

1 **Detection of human disease conditions by**
2 **single-cell morpho-rheological phenotyping of blood**

3
4 Nicole Toepfner^{1,2,3}, Christoph Herold^{1,4}, Oliver Otto^{1,4,5}, Philipp Rosendahl^{1,4}, Angela
5 Jacobi¹, Martin Kräter⁶, Julia Stächele³, Leonhard Menschner³, Maik Herbig¹, Laura
6 Ciuffreda⁷, Lisa Ranford-Cartwright⁷, Michal Grzybek^{8,9}, Ünal Coskun^{8,9}, Elisabeth
7 Reithuber¹⁰, Geneviève Garriss¹⁰, Peter Mellroth¹⁰, Birgitta Henriques-Normark¹⁰, Nicola
8 Tregay², Meinolf Suttorp³, Martin Bornhäuser⁶, Edwin R. Chilvers², Reinhard Berner³,
9 Jochen Guck^{1,*}

10
11 **Affiliations**

12 ¹ Center of Molecular and Cellular Bioengineering, Biotechnology Center, Technische
13 Universität Dresden, Tatzberg 47/49, 01307 Dresden, Germany

14 ² Department of Medicine, University of Cambridge, Hills Road, Cambridge, CB20QQ, UK

15 ³ Department of Pediatrics, University Clinic Carl Gustav Carus, Technische Universität
16 Dresden, Fetscherstrasse 74, 01307 Dresden, Germany

17 ⁴ Zellmechanik Dresden GmbH, Tatzberg 47/49, 01307 Dresden, Germany

18 ⁵ ZIK HIKE, Universität Greifswald, Fleischmannstr. 42-44, 17489 Greifswald

19 ⁶ Department of Hematology and Oncology, University Clinic Carl Gustav Carus, Technische
20 Universität Dresden, Fetscherstrasse 74, 01307 Dresden, Germany

21 ⁷ Institute of Infection, Immunity and Inflammation, University of Glasgow, 120 University
22 Place, Glasgow G12 8TA, UK

23 ⁸ Paul Langerhans Institute Dresden of the Helmholtz Centre Munich at the University Clinic
24 Carl Gustav Carus, Technische Universität Dresden, Fetscherstrasse 74, 01307 Dresden,
25 Germany

26 ⁹ German Center for Diabetes Research (DZD e.V.), 85764 Neuherberg, Germany

27 ¹⁰Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 171 77

28 Stockholm, Sweden; Department of Clinical Microbiology, Karolinska University Hospital,

29 171 76 Stockholm, Sweden

30 * Correspondence to: jochen.guck@tu-dresden.de

31

32

33 **Abstract**

34 Blood is arguably the most important bodily fluid and its analysis provides crucial health
35 status information. A first routine measure to narrow down diagnosis in clinical practice is the
36 differential blood count, determining the frequency of all major blood cells. What is lacking
37 to advance initial blood diagnostics is an unbiased and quick functional assessment of blood
38 that can narrow down the diagnosis and generate specific hypotheses. To address this need,
39 we introduce the continuous, cell-by-cell morpho-rheological (MORE) analysis of diluted
40 whole blood, without labeling, enrichment or separation, at rates of 1,000 cells/sec. In a drop
41 of blood we can identify all major blood cells and characterize their pathological changes in
42 several disease conditions *in vitro* and in patient samples. This approach takes previous results
43 of mechanical studies on specifically isolated blood cells to the level of application directly in
44 blood and adds a functional dimension to conventional blood analysis.

45

46 **Keywords**

47 Real-time deformability cytometry, cell mechanics, spherocytosis, malaria, neutrophil
48 activation, infection, leukemia

49

50 **Introduction**

51 Blood is responsible for the distribution of oxygen and nutrients, and centrally involved in the
52 immune response. Consequently, its analysis yields crucial information about the health status
53 of patients. The complete blood count, the analysis of presence and frequency of all major
54 blood cells, constitutes a basic, routine measure in clinical practice. It is often accompanied
55 by analysis of blood biochemistry and molecular markers reflecting the current focus on
56 molecular considerations in biology and biomedicine.

57

58 An orthogonal approach could be seen in the study of the overall rheological properties of
59 blood. It is evident that the flow of blood throughout the body will be determined by its
60 physical properties in the vasculature, and their alterations could cause or reflect pathological
61 conditions (1-3). In this context, blood is a poly-disperse suspension of colloids with different
62 deformability and the flow properties of such non-Newtonian fluids have been the center of
63 study in hydrodynamics and colloidal physics (4). Probably due to the dominant importance
64 of erythrocytes, at the expense of sensitivity to leukocyte properties, whole blood rheology
65 has not resulted in wide-spread diagnostic application.

66

67 Focusing on the physical properties of individual blood cells has suggested a third possibility
68 to glean maximum diagnostic information from blood. Various cell mechanics measurement
69 techniques, such as atomic force microscopy (5-7), micropipette aspiration (1, 8-10) or optical
70 traps (11-13), have been used to show that leukocyte activation, leukemia, and malaria
71 infection, amongst many other physiological and pathological changes, lead to readily
72 quantifiable mechanical alterations of the major blood cells (5, 11, 14-18). These proof-of-
73 concept studies have so far been done on few tens of specifically isolated cells. This line of
74 research has not progressed towards clinical application for lack of an appropriate

75 measurement technique that can assess single-cell properties of sufficient number directly in
76 blood.

77

78 This report aims to close this gap by presenting a novel approach for high-throughput single-
79 cell morpho-rheological (MORE) characterization of all major blood cells in continuous flow.

80 Mimicking capillary flow, we analyse human blood without any labeling or separation at rates

81 of 1,000 cells/sec. We show that we can sensitively detect morphological and rheological

82 changes of erythrocytes in spherocytosis and malaria infection, of leukocytes in viral and

83 bacterial infection, and of malignant transformed cells in myeloid and lymphatic leukemias.

84 The ready availability of quantitative morphological parameters such as cell shape, size,

85 aggregation, and brightness, as well as rheological information of each blood cell type with

86 excellent statistics might not only inform further investigation of blood as a complex fluid. It

87 also connects many previous reports of mechanical changes of specifically isolated cells to a

88 measurement now done directly in blood. As such, it adds a new functional dimension to

89 conventional blood analysis — a MORE complete blood count — and, thus, opens the door to

90 a new era of exploration in investigating and diagnosing hematological and systemic disorders

91

92

93 **Results**

94 *Establishment of morpho-rheological analysis*

95 In order to establish the normal MORE phenotype of cells found in blood, we obtained

96 venous, citrate-anticoagulated blood of healthy donors, of which 50 μ l was diluted in 950 μ l


97 of measurement buffer with a controlled elevated viscosity, but without any additional

98 labeling, sorting, or enrichment. The cell suspension was then pumped through a micro-

99 channel not unlike micro-capillaries in the blood vasculature (Figure 1A). Brightfield images

100 of the cells, deformed by hydrodynamic shear stresses in the channel (19), were obtained

101 continuously by RT-DC (20) (see Methods; Movie S1). These images revealed distinct
102 differences in overall morphology, brightness, and amount of deformation between all major
103 cell types found in blood (Figure 1B). RT-DC further enabled the continuous, real-time
104 quantification of the cross-sectional area and of the deformed shape (see detailed description
105 in Methods and Figure 1–Figure Supplement 1) of an, in principle, unlimited number of cells
106 at measurement rates of 100 – 1,000 cells/sec (Figure 1C). For each cell detected and
107 analyzed, an image was saved and the average pixel brightness within the cell determined
108 (Figure 1D, Figure 1–Figure Supplement 1). This single-cell MORE analysis of blood
109 revealed distinct and well-separated cell populations in the space spanned by the three
110 parameters (Movie S2). Notably, size and brightness alone — parameters not unlike those
111 accessible by light scattering analysis in standard flow cytometers — were sufficient for the
112 identification of the cell types (Figure 1D), so that deformation as additional, independent
113 parameter was available for assessing their functional changes. The identity of the individual
114 cell populations by size and brightness was established by magnetic cell sorting, controlled by
115 fluorescence immunophenotyping, and subsequent MORE analysis (Figure 1–Figure
116 Supplement 2). A key feature is the very clear separation of the abundant erythrocytes (red
117 blood cells; RBCs) from other cells as a result of their much greater deformation and lower
118 brightness. This feature gives access to leukocyte properties directly in diluted whole blood,
119 without the potentially detrimental effects of hemolysis (see Figure 1–Figure Supplement 3)
120 or other separation steps, which are required for analysis with cell mechanics techniques with
121 lower specificity and throughput, or non-continuous measurement. This aspect contributes to
122 the well-established field of hemorheology the possibility to interrogate mechanical properties
123 of all individual blood cells and to specifically investigate their contribution to the overall
124 blood rheological properties.



125

126 **Figure 1 | Single-cell, morpho-rheological phenotyping of blood.**

127 **A**, Analysis of whole, diluted blood. Hydrodynamic shear forces (red arrows) induce
 128 deformation of cells passing a microfluidic channel ($20 \times 20 \mu\text{m}^2$) at speeds of more than
 129 30 cm/s (blue arrows). **B**, Representative images of blood cell types acquired. Scale bar is 10
 130 μm . Images are analyzed for cell size as well as **C**, cell deformation and **D** average cell
 131 brightness. Each dot represents one of N measurement events. **E**, Normal range of
 132 deformation and size of cell populations from healthy donors. Each diamond represents the
 133 median of one donor; transparent ellipses indicate 95% confidence areas. **F**, Comparison of
 134 MORE cell counts with conventional blood count.

135


136 In extensive tests of the variability of this approach, MORE phenotyping yielded identical
 137 results in repeated measurements of blood from the same donor, with sodium citrate added as
 138 an anti-coagulant and for different storage times (Figure 1–Figure Supplement 4), between
 139 different donors of both sexes (Figure 1–Figure Supplement 5), and blood samples taken at
 140 different times during the day (Figure 1–Figure Supplement 6). This robustness served to
 141 establish a norm for the different cell types (Figure 1E). MORE analysis provided the identity

142 and frequency of all major white blood cells as with a conventional differential blood count
143 (Figure 1F; Supplementary file 1) — obtained from a single drop of blood, with minimal
144 preparation, and within 15 min. Going beyond this current gold-standard of routine blood cell
145 analysis, and importantly also beyond all other single-blood-cell mechanical analysis studies
146 to date, MORE phenotyping allowed the sensitive characterization of pathophysiological
147 changes of individual cells directly in merely diluted whole blood. In the following, we
148 exemplarily demonstrate, in turn for each of the blood cell types, the new possibilities of
149 gaining MORE information from an initial blood test as a time-critical step in generating
150 specific hypotheses and steering further investigation enabled by this approach.

151

152 ***Detection of morpho-rheological changes in erythrocytes***

153 Spherocytosis is a prototypical hereditary disease in humans in which genetic changes (here
154 ankyrin and spectrin mutations) cause abnormal shape and mechanical properties of
155 erythrocytes. Current diagnosis is based on the detection of abnormal cell shapes in a blood
156 smear, followed up by assessment of the osmotic fragility quantified by the Acidified
157 Glycerol Lysis Time (AGLT) or by osmotic gradient ektacytometry. These manual assays
158 take time and do not lend themselves to quick, initial screening. MORE analysis of the blood
159 of patients with spherocytosis directly revealed significantly less deformed and smaller
160 erythrocytes than normal (Figure 2A-C) as the functional correlate of the cytoskeletal
161 mutation. The differences are so clear (Figure 2-Figure Supplement 1) that this analysis can
162 serve as a fast primary and cheap screening test for spherocytosis. Detection of such RBC
163 changes would then warrant confirmation by more specific analysis using flow-cytometric
164 detection of Eosin-5-Maleimide staining (EMA test) or the direct detection of the mutation by
165 PCR, which require specific preparation, are more expensive, and thus benefit from a strong
166 and clear initial hypothesis.



167

168 **Figure 2 | Detection of RBC pathologies — spherocytosis and malaria.**

169 Exemplary density plots of RBC size vs. deformation in samples from **A**, healthy donor and
 170 **B**, patient with spherocytosis. **C**, Relative median RBC deformation and size in patients with
 171 spherocytosis (orange, $n = 4$ patients) compared to controls (black, $n = 21$ donors as in Figure
 172 1E with 68 % and 95 % confidence ellipses). Density plots of size vs. deformation of **D**,
 173 control RBCs and **E**, RBCs exposed to *P.f.* (blue), both after 12 h incubation. Scale bars, 10
 174 μm . **F**, Evolution of RBC deformation over 46 h time course of control (black), *P.f.* exposed
 175 (blue) and *P.f.* infected RBCs (red); open squares and diamonds, mean \pm SD, $n = 2$; filled
 176 squares, individual medians, ** $p < 0.01$, *** $p < 0.001$. **G**, 2BP-treated RBCs compared to
 177 PA- and non-treated controls (mean \pm SD of population medians, $n = 4$ donors, * $p < 0.05$).
 178 **H**, Reduced parasitemia in 2BP- compared to PA- and non-treated controls at 2 and 4 days
 179 post infection. Error bars: SD binomial, * $p < 0.0125$.

180

181 A change in RBC deformability has also been implicated in malaria pathogenesis, since single
 182 cells infected by parasites have been reported to be stiffer (17). This insight has not
 183 progressed towards clinical application and the gold standard in malaria diagnosis is still a

184 manual thick blood smear analysis. To evaluate whether MORE analysis could provide a
185 sensitive, automated alternative, we analyzed populations of RBCs exposed *in vitro* to
186 *Plasmodium falciparum* (*P.f.*) with a parasitemia (percentage of actually infected cells) of 7 –
187 8 % at time points over the 2 day parasite life cycle. We found a clear, significant, and
188 increasing reduction in the deformation of the entire exposed RBC population detectable after
189 4 h (Figure 2D-F; Figure 2–Figure Supplement 2). Inspection of the individual cell images
190 revealed the appearance of characteristic features likely associated with the maturation of
191 parasite inside a subset of RBCs (Figure 2D, E insets; Figure 2–Figure Supplement 2). These
192 features permitted the direct identification of positively infected cells, whose relative
193 frequency peaked at 36 h (Figure 2–Figure Supplement 2). The separate assessment of overtly
194 infected cells showed an even greater deformation reduction than observed in the entire
195 exposed population (Figure 2F; Figure 2–Figure Supplement 2), which — extrapolating our *in*
196 *vitro* results to the situation *in vivo* — relates to the possibility of clearance of stiff, infected
197 cells from the circulation by the spleen (21, 22). However, this small fraction of stiffer cells
198 alone cannot account for the reduced deformation of the whole population, so that a bystander
199 stiffening of exposed but non-infected cells seems involved (13).

200

201 Reduced membrane-cytoskeleton interactions have previously been correlated with
202 elliptocytic RBCs and resistance to *P.f.* infection (23). The characteristic biconcave
203 morphology of RBCs can be chemically altered by the use of 2-bromo-palmitate (2BP), an
204 efficient inhibitor of palmitoyl acyltransferases (24). Here, 2BP-treated RBC samples showed
205 changes in deformation (Figure 2G) with a concurrent reduction in *P.f.* infectivity (Figure
206 2H), compared to buffer control or RBCs treated with palmitic acid (PA). PA is an analogue
207 of 2BP that does not inhibit palmitoylation (24). Since both, 2BP and PA readily accumulate
208 in the membranes, but only 2BP causes a reduction in infectivity of *P.f.*, we suggest that
209 palmitoylation of RBC proteins is important for RBC morphology and infectivity of *P.f.*


210 While a previous report had found no change in infectability of RBCs treated with 2BP (25),
211 the difference could stem from the different RBC receptors involved in invasion by the
212 different parasite clones (3D7 vs. HB3), which in turn are differentially affected by
213 palmitoylation. Thus, MORE analysis has the potential to not only simplify, automate, and
214 speed up malaria diagnosis, but also to provide additional quantitative information aiding
215 research into the pathogenesis of the disease (26).

216

217 ***Detection of morpho-rheological changes in leukocytes***

218 While RBC mechanics has already been used for clinical diagnostics using rheoscopes and
219 ektacytometers for over 40 years (14, 21, 27), leukocyte mechanics has not been utilized for
220 diagnostic purposes. This is likely due to their increased stiffness compared to RBCs and a
221 lack of convenient techniques capable of sufficiently deforming them in suspension — their
222 physiological state. Until recently, techniques with sufficient throughput, obviating the need
223 for specifically isolating the relevant cells of interest, which always bears the potential of
224 inadvertent cell change (see Figure 1–Figure Supplement 3), did not exist. In this sense, the
225 mechanical phenotyping of diagnostic changes of leukocytes directly in diluted whole blood
226 is the most transformative application area of MORE analysis. For example, there have been
227 proof-of-concept studies on the mechanical changes associated with activation of isolated
228 neutrophils showing a stiffening, in line with the pronounced actin cortex that is a hallmark of
229 neutrophil activation (5, 16). MORE analysis of the *in vitro* neutrophil activation in blood
230 with the bacterial wall-derived tripeptide fMLP confirmed that neutrophils were indeed less
231 deformed and smaller within the first 15 min post fMLP treatment. Interestingly, the
232 subsequent time-course showed a reversal to more deformed and larger cells (Figure 3A, B;
233 Figure 3–Figure Supplement 1). These observations by themselves do not permit a conclusion
234 about a change in cell stiffness, since a smaller size also leads to less stress acting on the cells
235 in the channel, and less deformation (19, 28). Thus, we also calculated the apparent Young's

236 modulus of the cells, which increased from $E = 742 \pm 12$ Pa to $E = 853 \pm 20$ Pa (mean \pm SEM.
 237 $p = 0.009$, $n = 5$) during the first 15 min, and then subsequently reverted to values statistically
 238 indistinguishable but slightly lower than before stimulation (15 – 30 min: $E = 717 \pm 9$ Pa,
 239 $p = 0.347$; 30 – 45 min: $E = 719 \pm 7$ Pa, $p = 0.117$; 45 – 60 min: $E = 731 \pm 11$ Pa, $p = 0.465$).
 240 Such mechanical activation kinetics of neutrophils has not been reported before as the lower
 241 measurement rate of previous techniques yielded only cumulative data over the time period
 242 investigated.
 243
 244 We found a similar increase in size and greater deformation of the neutrophils at the later time
 245 points also in an experimental medicine trial, where healthy human volunteers inhaled
 246 lipopolysaccharide (LPS; from *E. coli*) (Figure 3A, B; Figure 3–Figure Supplement 1). Also,
 247 infecting blood *in vitro* with *Staphylococcus aureus* (*S. aureus*), a Gram-positive bacterium
 248 and one of the major pathogens responsible for life-threatening infections world-wide,
 249 resulted in larger and more deformed neutrophils, measured between 30 – 60 min after blood
 250 stimulation (Figure 3A, B; Figure 3–Figure Supplement 2).



251

252 **Figure 3 | Identification of leukocyte activation and infection *in vitro* and *in vivo*.**

253 Relative change (mean \pm SD) in **A**, deformation and **B**, size of neutrophils in diluted whole

254 blood after fMLP ($n = 5$ donors; see Figure 3–Figure Supplement 1) and *S. aureus* ($n = 4$

255 donors; see Figure 3–Figure Supplement 2) stimulation *in vitro* measured 15 – 30 min and

256 30 – 60 min after stimulation, respectively, and LPS inhalation ($n = 2$ donors; see Figure 3–

257 Figure Supplement 1) *in vivo* measured 135 min after inhalation. Exemplary scatter plots of

258 size vs. deformation of neutrophils in blood of a patient with **C**, ALI (magenta) and **D**, RTI

259 (green) compared to controls (black). Medians of size and deformation of **E**, **I**, neutrophils, **F**,

260 **J**, monocytes, and **G**, **K**, lymphocytes in blood samples of patients with E, F, G, ALI ($n = 4$

261 patients; magenta) and RTI ($n = 6$ patients; green), and I, J, K, EBV infection ($n = 5$ patients;

262 orange) relative to the norm (black, $n = 21$ donors as in Figure 1E with 68 % and 95 %

263 confidence ellipses). **H**, **I**, Mean and SD of these results, * $p < 0.05$. For typical scatter plots

264 of size vs. deformation of all three cell types and all three disease conditions see Figure 3–

265 Figure Supplement 3.

266

267 Congruently, blood taken from patients with an acute lung injury (ALI) of most likely

268 bacterial origin had larger and more deformed neutrophils compared to healthy controls

269 (Figure 3C, E, H). The same neutrophil response was found in blood samples from patients

270 hospitalized with viral respiratory tract infections (RTI; Figure 3D, E, H). Also monocytes

271 responded by a size increase in both RTI and ALI patients and after *in vitro* stimulation with

272 *S. aureus*, but only in viral RTI showed a significantly increased deformation, while blood

273 lymphocytes did not show any consistent response (Figure 3F-H; Figure 3–Figure

274 Supplement 2 and 3). The lymphocyte response changed when analyzing blood of patients

275 with acute Epstein-Barr-virus (EBV) infection, which is known to also stimulate the

276 lymphatic system, where both monocytes and lymphocytes showed an increase in cell size


277 and deformation, while neutrophils showed less of a response (Figure 3I-L, Figure 3–Figure

278 Supplement 3). These results suggest that MORE blood analysis might be sufficiently
 279 sensitive to distinguish bacterial from viral infections, and potentially other inflammatory
 280 diseases, by the differential response of the selective blood leukocyte populations. This
 281 possibility will be followed up in future specific trials. Importantly, MORE blood analysis is
 282 of special interest for blood tests in neonatology with patients at high risk of infections but
 283 only minute amounts of blood available for diagnostics, or to characterize neutrophils in
 284 neutropenic patients, as it merely requires longer data acquisition periods.

285

286 ***Detection of morpho-rheological changes in malignant transformed blood cells***

287 Blood cancers, or leukemias, affecting both myeloid and lymphoid cell lineages, are a further
 288 large area, where MORE analysis could potentially contribute fundamental insight, aid
 289 diagnosis, and improve therapy monitoring. While solid cancer cell mechanics has been a
 290 focus of cell mechanics research and extensively documented (29-31), the mechanical
 291 properties of blood cancers are comparatively understudied.



292

293 **Figure 4 | Detection and distinction of leukemia subtypes and monitoring of treatment**

294 **effects.** **A**, Normal brightness vs. size scatter plot of a healthy donor with the gates (shaded
 295 areas) used to identify lymphocytes (ly), basophils (ba), monocytes (mo), neutrophils (neu)
 296 and eosinophils (eo). **B**, Exemplary brightness vs. size scatter plot in AML; blast cells were

297 found in (ba) and (mo) gates. **C**, Exemplary brightness vs. size scatter plot in ALL; blast cells
298 were found in (ly), (ba), and (mo) gates. **D**, Medians of deformation and size for the
299 respective gates in blood samples of ALL (red circles, $n = 4$ patients) and AML patients
300 (purple triangles, $n = 7$ patients). Shaded areas in D (color as in A) represent 95% confidence
301 ellipses of the respective cell type norm ($n = 21$ donors, as in Figure 1E). Gray lines represent
302 lines of equal elasticity calculated for purely elastic objects. Scatter plots of ALL blast
303 deformation and size at **E**, one; **F**, seven, and **G**, twelve days post therapy start. Blue shaded
304 areas in E-H represent 95% confidence ellipses of the lymphocyte norm ($n = 21$ donors, as in
305 Figure 1E). **H**, Median deformation and size of ALL cells during 12 days of treatment (red
306 dots, days as numbers). Gray shaded areas surrounding data of days 1, 4, 8, and 12 represent
307 the 68 % (inner) and 95 % (outer) confidence area of a single measurement (according to
308 lymphocyte confidence in Figure 1–Figure Supplement 6H).

309

310 The available mechanics research on leukemic cells has been undertaken either on cell lines
311 or fully purified cells (1, 6-9, 11, 12, 16, 32) but so far not directly in blood. MORE analysis
312 of the blood of patients with acute myeloid (AML) and lymphatic leukemias (ALL) revealed
313 the new presence of atypical cell populations — the characteristic immature blasts not
314 normally present in healthy donors (Figure 4A-C). Cell populations gated for AML revealed
315 less deformed cells but at about the same size compared to healthy and fully differentiated
316 myeloid cells (Figure 4D, Figure 4–Figure Supplement 1), in line with previous results (6, 8,
317 9, 11, 12). ALL blast cells were larger in size compared to mature lymphocytes, but did not
318 show any consistent trend in deformation (Figure 4D; Figure 4–Figure Supplement 1). Since
319 cell size and deformation in the channel are interrelated (19, 20, 28), which can be seen by the
320 isoelasticity lines parameterizing the deformation-size space (Figure 4D), we also calculated
321 the apparent Young's modulus of these cells (Figure 4–Figure Supplement 1). These results
322 together show that mature lymphocytes, ALL blasts, mature myeloid cells, and AML blasts

323 have increasing levels of stiffness, consistent with the composite findings of previous reports
324 (1, 6-9, 11, 12, 16). This is quite different to the general trend in solid tumors, where cancer
325 cells are found to be more deformable than their healthy counterparts (29-31). Sensibly, the
326 differential stiffness of AML and ALL blasts, and its potential further increase with
327 chemotherapy, has been implicated in the occurrence of leukostasis (7, 16, 33). MORE
328 analysis might not only permit screening for novel therapeutic targets to soften cells (18, 34,
329 35), but also assessing the risk of leukostasis directly in each patient.

330
331 Finally, by following the ALL blast population in a patient over 12 days of
332 methylprednisolone treatment we could monitor the return to the normal morpho-rheological
333 fingerprint of blood (Figure 4E-H). The evolution of this fingerprint likely comprises multiple
334 contributions with blast cells undergoing apoptosis over a time course of 2 – 7 days (36),
335 which is associated with an increase in stiffness (33). Blast cells are sequestered by the spleen
336 and new, but immature and likely stiffer, blast cells are being added to the circulation from
337 the bone marrow. There could also be ALL subclones with different morpho-rheological
338 characteristics that respond differently and at different times to treatment. And the final
339 increase in deformation from day 9 to 12 coincides with the addition of cytostatic drugs
340 (vincristine, adriamycine) to the methylprednisolone treatment. Dissecting this multifaceted
341 response will be aided by adding simultaneous fluorescence identification of the cells in the
342 future (37). Of note, of the conventional biomarkers and techniques that are used in the
343 diagnosis of leukemia (see Supplementary file 2), only morphological analysis of air-dried
344 Romanowsky-stained blood (or bone marrow) smears is currently applied to monitor
345 treatment success in ALL. The response to treatment is one of the most powerful prognostic
346 *in vivo* markers of leukemia survival. In pediatric ALL the number of blasts at day 8 after start
347 of methylprednisolone treatment is predictive of the relapse rate (< 1,000 blasts/ μ l of blood:
348 relapse rate 20 – 30%; >1,000 blasts/ μ l of blood: relapse rate 50 – 80%). MORE analysis

349 provides at least the same information as conventional morphological analysis, but in a
350 shorter amount of time and with smaller sample sizes required (for a comparison between
351 MORE analysis and conventional biomarkers, see Supplementary file 2). In summary, MORE
352 blood analysis can be used to monitor morpho-rheological effects of chemotherapy and the
353 successful replacement of lymphoblasts with mature lymphocytes in a quantitative manner.
354 This last finding also touches upon the study of hematopoietic differentiation of cells in the
355 bone marrow, which is an obvious further potential area of application of this approach.

356

357 **Discussion and Conclusion**

358 Morpho-rheological phenotyping allows individual blood cell mechanics to be studied in a
359 range of human diseases and takes cell mechanical phenotyping to an entirely new level.
360 While established techniques such as micropipette aspiration (1, 8-10), indentation by cell
361 pokers and atomic force microscopes (5-7), or optical trapping (11-13) have provided
362 important proof-of-concept insight over the last decades, the recent advent of microfluidic
363 techniques approaching the throughput of conventional flow cytometers (18, 20, 32, 38, 39)
364 has finally brought mechanical phenotyping close to real-world applications (31, 40).
365 Amongst the latter techniques, RT-DC stands out because it can continuously monitor an, in
366 principle, unlimited number of cells, which enables the direct sensitive assessment of the state
367 of all major cell types found in blood. A volume as small as 10 μ l can be analyzed cell-by-
368 cell, with only dilution in measurement buffer to adjust cell density and prevent
369 sedimentation, but no labeling, enrichment or separation, which could otherwise cause
370 inadvertent activation of blood cells. The conventional blood count is extended by
371 information about characteristic, and diagnostic, morpho-rheological changes of the major
372 cell types. Cell mechanics and morphology are inherent and sensitive markers intimately
373 linked to functional changes associated with the cytoskeleton (41-45) and other intracellular
374 shape-determining and load-bearing entities (46, 47). Thus, label-free, disease-specific

375 morpho-rheological blood signatures are a novel resource for generating hypotheses about the
376 underlying molecular mechanisms. The availability of such parameters in real-time, easily
377 combined with conventional fluorescence detection (37), are the necessary prerequisite for
378 future sorting of morpho-rheologically distinct subpopulations, which then provides a novel
379 opportunity for further molecular biological analysis. Of course, at present, MORE
380 phenotyping provides a sensitive, but not a very specific marker. For example, neutrophil
381 softening could be a signature of different underlying pathological changes. In the future,
382 fuller exploration of the large combinatorial space afforded by the multi-parametric response
383 of the various blood cells, exploiting many additional morpho-rheological parameters in
384 conjunction with machine learning, and inclusion of conventional fluorescence-based marker
385 analysis (37) will further increase the specificity of this approach. Apart from now enabling
386 realistic blood cell research *ex vivo* close to physiological conditions, delivering for example
387 previously unavailable information about leukocyte activation kinetics, and after further in-
388 depth studies of the phenomena reported here, MORE phenotyping could have a tangible
389 impact on diagnosis, prognosis, and monitoring of treatment success of many hematological
390 diseases as well as inflammatory, infectious, and metabolic disorders. Beyond blood analysis,
391 MORE phenotyping has the potential to become a standard approach in flow cytometry with
392 many applications in biology, biophysics, biotechnology, and medicine.

393

394 **Materials and Methods**

395 Real-time deformability cytometry

396 Real-time deformability cytometry (RT-DC) was carried out as described previously
397 (20). For RT-DC measurements, cells were suspended in a viscosity-adjusted measurement
398 buffer (MB) based on 1x phosphate buffered saline (PBS) containing methylcellulose. The
399 viscosity was adjusted to 15 mPa s at room (and measurement) temperature, determined using
400 a falling ball viscometer (Haake, Thermo Scientific). Cells in the MB were taken up into a 1
401 ml syringe, placed on a syringe pump (neMESYS, Cetoni GmbH) and connected via tubing to
402 the sample inlet of the microfluidic chip with a square measurement channel cross section of
403 $20 \times 20 \mu\text{m}^2$. The microfluidic chip was made from cured polydimethylsiloxane bonded to a
404 thickness #2 cover glass. Another syringe containing MB without cells was connected to the
405 sheath flow inlet of the chip. Measurements were carried out at a total flow rate of $0.12 \mu\text{l/s}$
406 with a sample flow rate of $0.03 \mu\text{l/s}$ and a sheath flow rate of $0.09 \mu\text{l/s}$ unless stated
407 otherwise. Different gating settings for cell dimensions could be employed during the
408 measurement (Figure 1–Figure Supplement 1). Images of the cells in the channel were
409 acquired in a region of interest of 250×80 pixels at a frame rate of 2,000 fps. Real-time
410 analysis of the images was performed during the measurement and the parameters necessary
411 for MORE analysis were stored for all detected cells.

412

413 Data processing in MORE analysis

414 The raw data obtained from RT-DC measurements consisted of the following
415 information of every detected cell: a bright field image of the cell, the contour of the cell, its
416 deformation value, and the cell size as the cross-sectional area of the cell in the image (Figure
417 1–Figure Supplement 1). The deformation was calculated from the convex hull contour of the
418 cell — a processed contour, where all points contributing to concave curvature were removed:

$$deformation = 1 - \frac{2\sqrt{\pi A}}{l},$$

419 where A is the area enclosed by the convex hull contour and l is the length of the convex hull
420 contour. Therefore, deformation is the deviation from a perfectly circular cell image. It
421 describes the change of the cell's shape by the hydrodynamic forces in the measurement
422 channel but may also contain pre-existing shape deviations from a sphere, for example for the
423 biconcave, disk-like shapes of healthy red blood cells or strongly activated and polarized
424 neutrophils. Image brightness analysis was carried out using the contour information and the
425 image of the cell. The mean brightness of the cell was determined from all pixel values within
426 the cell's contour (Figure 1D). With this information the distinction of leukocyte
427 subpopulations was possible in the space spanned by cell size and mean brightness (Figure 1D
428 and Figure 1–Figure Supplement 2). It is worth noting that the absolute value of the resulting
429 brightness was influenced by several experimental conditions such as focus of the image and
430 the thickness of the microfluidic chip. However, this did not affect the quality of the
431 distinction of cells by their brightness. Special care had to be taken when comparing the
432 brightness of different purified leukocyte subpopulations of similar size (like neutrophils,
433 eosinophils, and monocytes). In order to achieve a situation similar to the diluted whole blood
434 measurement, we used the same microfluidic chip repeatedly after thorough flushing. All
435 brightness values reported were normalized to 100 by the background brightness of the
436 channel. Apart from the initial brightness distinction, in a second step, the root mean square of
437 pixel brightness values was calculated in an area of 9 x 5 pixels (9 in the flow direction, 5
438 perpendicular to the flow direction) around the geometrical center of the cell. This
439 information was used to distinguish the relevant leukocyte subpopulations from eventual
440 erythrocyte doublets present (Figure 1D). To ensure best validity of the deformation measure
441 based on the area within the cell's contour and the length of the contour, only cells without
442 prominent protrusions were considered for comparisons based on deformation. A reliable

443 criterion to select those cells was found by comparing the area within the originally detected
444 cell contour and within the convex hull contour. For erythrocytes, the difference of these two
445 areas was limited to 15 %. For leukocytes, a suitable limit was found at 5 %. For the
446 identification of malaria-infected erythrocytes we used a semi-automated procedure designed
447 to obtain only clearly positive results and to avoid false negatives. The defining property of
448 infected cells was the presence of bright spots within the cells. In a first step, all pixel values
449 outside the cell's contour were set to 0. In a twice-repeated procedure, the image of the
450 erythrocyte was further reduced by setting all pixel values of the contour pixels to 0 and
451 finding the new contour. This measure was used to eliminate possible bright spots due to
452 fringes at the border of the cell. From this image, the brightness of every pixel of the
453 remaining cell was calculated by taking the mean of the pixel itself and its 8 nearest
454 neighbors. The user was then able to set the minimal threshold for this brightness in order to
455 identify a cell as potentially infected. Since higher pixel values are frequently obtained at the
456 rear of the cell (in flow direction) only bright spots within 70 % of the cell's length counted
457 from the front of the cell were considered. As a last criterion, the calculated brightness was
458 compared to the brightness of the cell directly surrounding the bright spot in order to
459 eliminate cases of generally bright cells. For this a mean brightness value was formed from all
460 pixels located within the two rectangular areas spanned from $[k-3, l-1]$ to $[k-2, l+1]$ as well as
461 $[k+2, l-1]$ to $[k+3, l+1]$, where k is the pixel position of the bright spot in the flow direction and
462 l is the pixel position of the bright spot orthogonal to the flow direction. Most of this analysis
463 can be performed with ShapeOut, except for the last aspect of considering details of internal
464 brightness, for which a custom-written Python script was used.

465

466 Blood measurements

467 All studies complied with the Declaration of Helsinki and involved written informed
468 consent from all participants or their legal guardians. Ethics for experiments with human

469 blood were approved by the ethics committee of the Technische Universität Dresden
470 (EK89032013, EK458102015), and for human blood and LPS inhalation in healthy volunteers
471 by the East of England, Cambridge Central ethics committee (Study No. 06/Q0108/281 and
472 ClinicalTrialReference NCT02551614). Study participants were enrolled according to good
473 clinical practice and recruited at the University Medical Centre Carl Gustav Carus Dresden,
474 Germany, the Biotechnology Center, Technische Universität Dresden, Germany, or
475 Cambridge University Hospitals, Cambridge, UK. Human blood and serum used to culture
476 the malaria parasites was obtained from the Glasgow and West of Scotland Blood Transfusion
477 Service; the provision of the material was approved by the Scottish National Blood
478 Transfusion Service Committee For The Governance Of Blood And Tissue Samples For Non-
479 Therapeutic Use. Venous blood was drawn from donors with a 20-gauge multifly needle into
480 a sodium citrate S-monovette (Sarstedt) by vacuum aspiration. In case of blood volumes
481 above 9 ml, blood was manually drawn via a 19-gauge multifly needle into a 40 ml syringe
482 and transferred to 50 ml Falcon polypropylene tubes (BD) containing 4 ml 3.8% sodium
483 citrate (Martindale Pharmaceuticals). For RT-DC measurements of blood, 50 μ l of anti-
484 coagulated blood were diluted in 950 μ l MB and mixed gently by manual rotation of the
485 sample tube. This fixed dilution of 1:20 was the result of optimization series to dilute as little
486 possible, while still enabling the reliable detection of single cell events for both erythrocytes
487 and leukocytes at typical cell densities found in blood. Measurements were typically carried
488 out within 2 h past blood donation unless stated otherwise. Two different gating settings were
489 employed in the measurement software for erythrocyte and leukocyte acquisition, respectively
490 (Figure 1–Figure Supplement 1A). For erythrocytes, gates were essentially open allowing cell
491 dimensions in flow direction from 0 μ m to 30 μ m. The leukocyte gate was set to a size of 5 –
492 16 μ m in flow direction and > 5 μ m perpendicular to it. This setting allowed filtering out
493 single erythrocytes and almost all erythrocyte multiples. The leukocyte populations remained
494 unaltered as confirmed in experiments with purified leukocytes at open gate settings. Using

495 the leukocyte gate, the majority of thrombocytes was also ignored as they possess typical
496 diameters of 2 – 3 μm . A small fraction of very large thrombocytes and microerythrocytes
497 were still found within this gate as seen in Figure 1C and D. Mechanical analysis of these
498 events constitutes an interesting challenge in that they can be detected and counted, but at
499 present not tested for activation via their deformation given their very small size compared to
500 the channel size, which was chosen to accommodate all cells found in blood. Measurements
501 in the leukocyte gate were carried out over a fixed timespan of 15 min (to acquire typically
502 500 to 3,000 leukocytes, depending on donor and disease state), followed by a separate
503 measurement in the erythrocyte gate for a few seconds until data of 5,000 – 10,000 cells were
504 acquired. Measurements for establishing the normal MORE blood phenotype in healthy
505 human volunteers (Figure 1E), and all measurements directly compared to this norm, e. g.,
506 blood samples derived from patients, were carried out at a temperature of 30 °C. The
507 remaining measurements — fMLP stimulation, LPS stimulation, purified leukocyte
508 subpopulations, malaria infection, and erythrocyte palmitoylation — were carried out at a
509 temperature of 23 °C. The viscosity of the MB was always adjusted to 15 mPa s at the
510 different temperatures to keep the acting hydrodynamic stress and, thus, the resulting
511 deformation regimes the same. An MB with the viscosity of 25 mPa s (to slow blood cell
512 sedimentation in the tubing) was used in experiments for comparing the relative cell count
513 results of leukocyte subpopulation by MORE analysis and conventional blood count (Figure
514 1F; Supplementary file 1). Here, the total flow rate was 0.06 $\mu\text{l/s}$ (sample flow 0.015 $\mu\text{l/s}$,
515 sheath flow 0.045 $\mu\text{l/s}$) and images were acquired at 4,000 fps.

516

517 Leukocyte purification and identification

518 Leukocyte subpopulations were purified by negative and/or positive magnetic-activated
519 cell sorting (MACS) following the instructions provided by the manufacturer. Reagents for
520 cell isolation with magnetic beads purchased from Miltenyi Biotec were MACSxpress

521 Neutrophil Isolation Kit human (130-104-434), Monocyte Isolation Kit human (130-091-
522 153), Basophil Isolation Kit II human (130-092-662), Pan T Cell Isolation Kit human (130-
523 096-535) and CD3 MicroBeads (130-050-101), as well as Pan B Cell Isolation Kit human
524 (130-101-638) and CD19 MicroBeads (130-050-301). EasySep Human Eosinophil
525 Enrichment Kit (19256) was obtained from StemCell Technologies. The purity of the derived
526 cell isolates was controlled twice by staining with 7-Color-Immunophenotyping Kit (Miltenyi
527 Biotec, 5140627058), as well as additional single staining of each cell subset for
528 fluorescence-activated cell sorting (FACS). Individual cell type staining antibodies from
529 BioLegend were used for granulocytes (target: CD66ACE, staining: PE, order no.: 342304,
530 RRID:AB_2077337), eosinophils (Siglec-8, APC, 347105, RRID:AB_2561401), B
531 lymphocytes (CD19, FITC, 302205, RRID:AB_314235), NK cells (CD56, PE, 318305,
532 RRID:AB_604093), T helper cells (CD4, PE-Cy7, 300511, RRID:AB_314079), T
533 lymphocytes (CD3, APC, 300411, RRID:AB_314065), cytotoxic T cells (CD8, PacificBlue,
534 301026, RRID:AB_493111), monocytes (CD14, FITC, 325603, RRID:AB_830676), as well
535 as eosinophils, basophils, mast cells, and mononuclear phagocytes (CD193, PE, 310705,
536 RRID:AB_345395). For RT-DC measurements, purified cells were pelleted by centrifugation
537 (200 g, 5 min) and re-suspended in MB at concentrations of about $5 \cdot 10^6$ cells/ml by
538 repeated, gentle shaking.

539

540 *In vitro* malaria infection

541 *Plasmodium falciparum* (*P. falciparum*, HB3 clone, NCBI Taxonomy ID: 137071)
542 cultures were grown accordingly to standard protocols (48). Two *P. falciparum* cultures were
543 grown independently for 3 weeks, treated with Plasmion (49) to enrich for the schizont stages,
544 and then allowed to reinvade fresh red blood cells in a shaking incubator for 3 h. The cultures
545 were then treated with sorbitol (50), to remove all schizonts that had not reached full maturity;
546 only ring stage parasites survive sorbitol treatment. The highly synchronized culture used for

547 the RT-DC measurements therefore consisted of erythrocytes exposed to *P. falciparum*, into
548 some of which parasites had invaded within a 3 h window. Samples were removed at 4, 12,
549 16, 20, 24, 36, 42 and 46 hours post invasion for the RT-DC measurements. At the time of
550 each measurement a thin blood smear was taken and stained with Giemsa's stain to assess the
551 parasitemia and the stage of the parasites (Figure 2–Figure Supplement 2A). A control sample
552 of the same blood without the parasites underwent the identical treatment as the *P. falciparum*
553 exposed samples. For RT-DC measurements, at each time point, 10 μl of the blood culture
554 were diluted in 990 μl of the MB to a final concentration of $2.5 \cdot 10^5$ cells/ μl . The total flow
555 rate through the channel was 0.04 $\mu\text{l/s}$ for all malaria infection experiments (sample flow rate
556 0.01 $\mu\text{l/s}$, sheath flow rate 0.03 $\mu\text{l/s}$). For experiments on growth and invasion depending on
557 erythrocyte palmitoylation status, blood, treated as described in the palmitoylation section
558 below, was shipped from Germany to Scotland in PBS buffer containing 15 mM glucose, 5
559 mM sodium pyruvate, 5 μM Coenzyme A, 5 mM MgCl_2 , 5 mM KCl, 130 mM NaCl.
560 Parasites were synchronized by collecting *P. falciparum* mature stages (trophozoites and
561 schizonts) from *P. falciparum* clone HB3 using MACS columns (51). The trophozoite and
562 schizont enriched cultures were mixed with erythrocytes to achieve a starting parasitemia of
563 0.5 – 1.0 %. Each erythrocyte type was set up in a separate culture flask at 3 ml volume and 5
564 % hematocrit. The parasites were incubated in a shaking incubator at 37 °C under standard
565 culture conditions of gas and medium. Parasitemia was monitored on day 2 (post invasion)
566 and day 4 (second round of invasion). For all experimental conditions, a minimum of 500
567 RBCs were counted. Experiments were repeated on 3 different days with erythrocytes of 3
568 different donors yielding the same results.

569

570 Palmitoylation of erythrocytes

571 Red blood cells were pelleted by blood centrifugation (800 g, 5 min), plasma was
572 removed, and the RBCs were pretreated with one volume of 1 % fatty acid-free bovine serum

573 albumin (BSA) in PBS-glucose (10 mM phosphate, 140 mM NaCl, 5 mM KCl, 0.5 mM
574 EDTA, 5 mM glucose, pH7.4) at 37° C for 15 min, in order to lower the endogenous content
575 of free fatty acids in their membrane pools, and washed three times with PBS-glucose. Cells
576 were re-suspended in 3 volumes of incubation buffer, containing 40 mM imidazole, 90 mM
577 NaCl, 5 mM KCl, 5 mM MgCl₂, 15 mM D-glucose, 0.5 mM EGTA, 30 mM sucrose, 5 mM
578 sodium pyruvate, 5 mM Coenzyme A, 50 mg PMSF/ml and 200 U penicillin/streptomycin
579 (320 mOsm, pH 7.6). For inhibition of palmitoylation, 100 µM final concentration of 2-
580 bromopalmitate (2BP) was used. 100 µM palmitic acid (PA) was added as a control. The
581 RBCs were incubated in a humidified incubator with 5 % CO₂ for 24 h at 37 °C. Prior to
582 measurement, RBCs were pelleted, re-suspended in 1 % BSA, incubated for 15 min at 37 °C
583 and washed two times with PBS-glucose. Glucose, sucrose, 2-bromopalmitate, palmitic acid,
584 fatty acid free BSA, Coenzyme A, and PMSF were purchased from Sigma-Aldrich;
585 Penicillin/streptomycin and sodium pyruvate from Gibco. RT-DC measurements were carried
586 out at a room temperature of 23°C and with a total flow rate of 0.032 µl/s (sample flow 0.008
587 µl/s, sheath flow 0.024 µl/s) after adding 10 µl of the RBC suspension to 990 µl of MB.
588 Experiments were carried out on 2 different days with erythrocytes of 4 different donors.

589

590 fMLP-induced neutrophil activation

591 For *in vitro* fMLP stimulation, blood was stimulated with 100 nM N-Formylmethionyl-
592 leucyl-phenylalanine (fMLP; Sigma-Aldrich, 47729, 10 mg-F). Separate samples were
593 analyzed in time intervals of 0 – 15 min, 15 – 30 min, 30 – 45 min, and 45 – 60 min after
594 activation. During incubation all samples were stored in 2 ml Eppendorf tubes at 37°C at 450
595 rpm in a ThermoMixer C (Eppendorf). All experiments were performed within 2 hours
596 maximum after blood drawing. Experiments were repeated with blood samples of 5 different
597 donors on 5 different days. Due to experimental feasibility PBS controls of these donors were
598 measured before fMLP stimulation and after the 60 min fMLP sample. Additionally, three

599 control samples of different donors were treated similarly adding 10 µl 1 x PBS instead of
600 fMLP and were analyzed in time intervals of 0 – 15 min, 15 – 30 min, 30 – 45 min, and 45 –
601 60 min after bleeding to exclude kinetic effects due to blood alteration with storage.

602

603 *In vitro Staphylococcus aureus* infection

604 Blood stimulation was performed with *Staphylococcus aureus* Newmann strain (*S.*
605 *aureus*; ATCC 25904; NCBI Taxonomy ID: 426430). For reproducible repetitive testing with
606 competent bacterial strains cryo-aliquots of *S. aureus* were prepared as follows. Bacterial cells
607 were pre-cultured to the log phase for synchronization of growth in BHI broth (Bacto Brain
608 Heart Infusion, Becton Dickinson) at 37°C and transferred to a second culture. Aiming at a
609 high bacterial virulence factor expression, the cells were grown to an early stationary phase in
610 a 96-well-plate (100 µl, OD_{600nm} 0.1837, Infinite 200 reader, TECAN), pelleted by
611 centrifugation (2671 g for 5 min at 4 °C), washed two times in PBS and re-suspended in cell-
612 freezing media (Iscove Basal Medium, Biochrom) with 40 % endotoxin-free FBS (FBS
613 Superior, Biochrom) at a final concentration of $2.54 \cdot 10^9$ CFU/ml. Aliquots were immediately
614 frozen at –80 °C and only thawed once for a single experiment. Blood stimulation and
615 measurement were carried out at 30 °C temperature for 15 min with one multiplicity of
616 infection (MOI) in 1:20 RT-DC measurement buffer. MOI (0.9 - 1.09) was controlled
617 retrospectively by granulocyte count and 5 % sheep blood agar culture (Columbia agar,
618 bioMérieux) at 37 °C and bacterial colony counting on the following day. PBS blood controls
619 were conducted before and after *S. aureus* blood stimulation. The experiment was
620 repeated with blood of 4 different donors on 4 different days. All experiments were performed
621 within 2 h after blood drawing.

622

623 LPS inhalation

624 *E. coli* lipopolysaccharide (LPS) 50 µg (GSK) was administered to healthy, never-
625 smoker volunteers via a specialized dosimeter (MB3 Markos Mefar) 90 minutes prior to
626 injection of autologous ^{99m}Techneium-Hexamethylpropleneamine-oxime labeled neutrophils.
627 Temperature, forced expiratory volume in 1 second, forced ventilator capacity and triplicate
628 blood pressures were recorded prior to, and at 30 min intervals post LPS administration. RT-
629 DC measurements were obtained at baseline, 90, 135, 210, 330, and 450 min post LPS.

630

631 Respiratory tract infections (RTI) and acute lung injury (ALI)

632 Patient inclusion criteria for RTI: Patients with clinical signs of lower RTI, a core
633 temperature > 38.5°C and the need for supplemental oxygen were recruited on the day of
634 hospitalization. Only patients without treatment prior to hospitalization were included. None
635 of the included patients received antibiotic treatment for reconstitution. Patient inclusion
636 criteria for ALI: Patients diagnosed with ALI according to the criteria of the North American
637 European Consensus Conference (NAECC) (52) and without underlying diseases prior to ALI
638 were included. All blood samples were analyzed within 30 min of venipuncture. Size and
639 deformation of blood leukocytes was characterized for all blood cells in which the area within
640 the original cell contour differed less than 5 % from the area within the convex hull contour.

641

642 Acute myeloid/lymphatic leukemias

643 Samples from patients diagnosed with ALL or AML based on cytogenetic, molecular-
644 genetic and morphological criteria according to WHO classification from 2008 (53) were
645 assessed by MORE blood analysis on the day of diagnosis. In order to evaluate mechanical
646 properties of AML and ALL blast cells in diluted whole blood, several brightness and size
647 gates had to be combined as shown in Figure 4A-C. The AML gate spanned the regions
648 normally used for basophils and monocytes. The ALL gate spanned the regions used for
649 lymphocytes, basophils and monocytes. In all AML cases, blasts made up > 80 % of all

650 leukocytes, and up to 99 % of events in the AML gate. In all ALL cases, blasts made up > 60
651 % of leukocytes, and up to 85 % of events in the ALL gate. The blast cell fraction was
652 obtained from the standard differential blood count, by comparing the number of blast cells
653 with the number of normal cells that would also populate the respective blasts gate in MORE
654 analysis.

655

656 Isoelasticity lines and Young's moduli

657 RT-DC data of cell size and deformation can be converted into apparent Young's moduli
658 using theoretical models (19) and numerical simulations (28). To ensure a correct conversion,
659 effects of shear thinning of the MC medium and a deformation offset due to pixelation were
660 taken into account as described in (54). The calculation of apparent Young's moduli for
661 AML and ALL blasts and isoelasticity lines are based on the assumption that cells can be
662 approximated as purely elastic, homogeneous isotropic spheres. This assumption is equivalent
663 to using the Hertz model to extract an apparent Young's modulus of cells in atomic force
664 microscopy-enabled nano-indentation experiments. The conversion of deformation and size
665 into Young's modulus for every cell measured is included in the analysis software ShapeOut.

666

667 Statistics

668 Throughout, the number of cells in a single measurement is denoted as N , while the
669 number of independently repeated experiments — typically the number of donor or patient
670 samples measured, as stated — is denoted as n . For comparison of different donors or
671 treatment conditions the median of deformation and cell size of a specific cell population was
672 used. In order to evaluate effects of a disease we calculated a 2D confidence ellipse at 68.3 %
673 (or 1 sigma) as well as 95.5 % (or 2 sigma) for the control group/norm norm of healthy
674 human blood donors in the space of cell size and deformation. The confidence ellipse was
675 calculated from the covariance matrix of the data and the calculation was carried out with

676 OriginPro 2015 (Originlab). Statistically significant differences between two sets of
677 experiments were checked to the significance level of $p < 0.05$ by comparing the groups of
678 individual median values of an experiment using a Kruskal-Wallis one-way ANOVA as
679 implemented in OriginPro 2015 (Originlab). In erythrocyte MORE analysis in malaria
680 infection and palmitoylation, statistically significant differences were checked using linear
681 mixed models in combination with a likelihood ratio test to obtain significance levels for the
682 comparison of the complete populations (55). This analysis can be performed in the software
683 ShapeOut. One, two, or three asterisks were awarded for significance levels $p < 0.05$, $p <$
684 0.01 and $p < 0.001$, respectively. In manual counts of malaria infection in RBCs, statistical
685 analyses were performed using a χ^2 test with Bonferroni correction (adjusted statistical
686 significance for $p < 0.0125$) to compare the numbers of infected and non-infected erythrocytes
687 between erythrocyte samples, except where number of parasite infected cells was zero, in
688 which case Fisher`s exact test was used. The standard deviation for the parasitemia was
689 calculated assuming a binomial random variable as $SD = \sqrt{N \cdot p (1 - p)}$, where N is the
690 number of cells counted and p is the fraction of infected cells.

691

692 Data availability

693 The raw data of all measurements are available from the Dryad Digital Repository:
694 <https://doi.org/10.5061/dryad.2fk71>. The TDMS files can be read, processed, and analyzed
695 using ShapeOut, a custom written, open source software.

696

697 Code availability

698 RT-DC measurement software is commercially available. The analysis software
699 ShapeOut is available as an open source application on GitHub
700 (<https://github.com/ZELLMCHANIK-DRESDEN/ShapeOut/releases>).

701

702 **Acknowledgements**

703 The authors would like to thank Björn Lange, Michael Mögel, Beate Eger, Isabel Deinert,
704 Tamara Schön and the whole team for their contributions to patient recruitment, Claudia Krug
705 for cell isolation, Uta Falke and Isabel Richter for technical help, Thomas Krüger for help
706 with drawing blood, Ramona Hecker for technical advice, Mike Blatt for the loan of a
707 microscope, Elizabeth Peat for assistance with malaria parasite culture materials, Salvatore
708 Girardo of the BIOTEC/CRTD Microstructure Facility (in part funded by the European Fund
709 for Regional Development – EFRE) for help with preparation of PDMS chips, and Stephan
710 Grill for critical reading of the manuscript.

711

712 **Declaration of potential conflict of interest**

713 C.H., O.O and P.R. own shares of, and are part- or full-time employed at, Zellmechanik
714 Dresden GmbH, a company selling devices based on real-time deformability cytometry. The
715 authors have no other financial interests to declare. Zellmechanik Dresden GmbH did not
716 have any role in the conception and planning of this study, or its preparation for publication.

717

718 **REFERENCES**

719

- 720 1. Lichtman MA (1973) Rheology of Leukocytes, Leukocyte Suspensions, and Blood in
 721 Leukemia - Possible Relationship to Clinical Manifestations. *J Clin Invest* 52(2):350–
 722 358.
- 723 2. Baskurt OK, Meiselman HJ (2003) Blood rheology and hemodynamics. *Semin Thromb*
 724 *Hemost* 29(5):435–450.
- 725 3. Popel AS, Johnson PC (2005) Microcirculation and hemorheology. *Annu Rev Fluid*
 726 *Mech* 37(1):43–69.
- 727 4. Lan H, Khismatullin DB (2012) A numerical study of the lateral migration and
 728 deformation of drops and leukocytes in a rectangular microchannel. *Int J Multiphase*
 729 *Flow* 47(C):73–84.
- 730 5. Worthen GS, Schwab B, Elson EL, Downey GP (1989) Mechanics of stimulated
 731 neutrophils: cell stiffening induces retention in capillaries. *Science* 245(4914):183–186.
- 732 6. Rosenbluth MJ, Lam WA, Fletcher DA (2006) Force Microscopy of Nonadherent
 733 Cells: A Comparison of Leukemia Cell Deformability. *Biophys J* 90(8):2994–3003.
- 734 7. Lam WA, Rosenbluth MJ, Fletcher DA (2008) Increased leukaemia cell stiffness is
 735 associated with symptoms of leucostasis in paediatric acute lymphoblastic leukaemia.
 736 *Brit J Haematol* 142(3):497–501.
- 737 8. Lichtman MA (1970) Cellular Deformability During Maturation of Myeloblast -
 738 Possible Role in Marrow Egress. *N Engl J Med* 283(18):943–948.
- 739 9. Dombret H, et al. (1995) Changes in microrheology of acute promyelocytic leukemia
 740 cells during all-trans retinoic acid (ATRA) differentiation therapy: a mechanism for
 741 ATRA-induced hyperleukocytosis? *Leukemia* 9(9):1473–1477.
- 742 10. Ravetto A, Wyss HM, Anderson PD, Toonder den JMJ, Bouten CVC (2014)
 743 Monocytic Cells Become Less Compressible but More Deformable upon Activation.
 744 *PLoS ONE* 9(3):e92814.
- 745 11. Lautenschläger F, et al. (2009) The regulatory role of cell mechanics for migration of
 746 differentiating myeloid cells. *Proc Natl Acad Sci USA* 106(37):15696–15701.
- 747 12. Ekpenyong AE, et al. (2012) Viscoelastic Properties of Differentiating Blood Cells Are
 748 Fate- and Function-Dependent. *PLoS ONE* 7(9):e45237.
- 749 13. Paul A, Pallavi R, Tatu US, Natarajan V (2013) The bystander effect in optically
 750 trapped red blood cells due to Plasmodium falciparum infection. *Trans R Soc Trop Med*
 751 *Hyg* 107(4):trt010–223.
- 752 14. Schmid-Schönbein H, Weiss J, Ludwig H (1973) A simple method for measuring red
 753 cell deformability in models of the microcirculation. *Blut* 26(6):369–379.
- 754 15. Suresh S, et al. (2005) Connections between single-cell biomechanics and human


- 755 disease states: gastrointestinal cancer and malaria. *Acta Biomat* 1(1):15–30.
- 756 16. Rosenbluth MJ, Lam WA, Fletcher DA (2008) Analyzing cell mechanics in
757 hematologic diseases with microfluidic biophysical flow cytometry. *Lab Chip*
758 8(7):1062–1070.
- 759 17. Bow H, et al. (2011) A microfabricated deformability-based flow cytometer with
760 application to malaria. *Lab Chip* 11(6):1065–1073.
- 761 18. Gossett DR, et al. (2012) Hydrodynamic stretching of single cells for large population
762 mechanical phenotyping. *Proc Natl Acad Sci USA* 109(20):7630–7635.
- 763 19. Mietke A, et al. (2015) Extracting Cell Stiffness from Real-Time Deformability
764 Cytometry: Theory and Experiment. *Biophys J* 109(10):2023–2036.
- 765 20. Otto O, et al. (2015) Real-time deformability cytometry: on-the-fly cell mechanical
766 phenotyping. *Nat Methods* 12(3):199–202.
- 767 21. Cranston HA, et al. (1984) Plasmodium falciparum maturation abolishes physiologic
768 red cell deformability. *Science* 223(4634):400–403.
- 769 22. Shelby JP, White J, Ganesan K, Rathod PK, Chiu DT (2003) A microfluidic model for
770 single-cell capillary obstruction by Plasmodium falciparum-infected erythrocytes. *Proc*
771 *Natl Acad Sci U S A* 100(25):14618–14622.
- 772 23. Chishti AH, Palek J, Fisher D, Maalouf GJ, Liu SC (1996) Reduced invasion and
773 growth of Plasmodium falciparum into elliptocytic red blood cells with a combined
774 deficiency of protein 4.1, glycophorin C, and p55. *Blood* 87(8):3462–3469.
- 775 24. Biernatowska A, et al. (2013) The role of MPP1/p55 and its palmitoylation in
776 resting state raft organization in HEL cells. *Biochim. Biophys. Acta* 1833:1876-
777 1884.
- 778 25. Jones ML, Collins MO, Goulding D, Choudhary JS, Rayner JC (2012) Analysis of
779 protein palmitoylation reveals a pervasive role in Plasmodium development and
780 pathogenesis. *Cell Host Microbe* 12(2):246–258.
- 781 26. Koch M, et al. (2017) Plasmodium falciparum erythrocyte-binding antigen 175 triggers
782 a biophysical change in the red blood cell that facilitates invasion. *Proc Natl Acad Sci*
783 *USA* 114(16):4225–4230.
- 784 27. Reid HL, Dormandy JA, Barnes AJ, Lock PJ, Dormandy TL (1976) Impaired red cell
785 deformability in peripheral vascular disease. *Lancet* 1(7961):666–668.
- 786 28. Mokbel M, et al. (2017) Numerical Simulation of Real-Time Deformability Cytometry
787 To Extract Cell Mechanical Properties. *ACS Biomaterials*.
788 doi:10.1021/acsbiomaterials.6b00558.
- 789 29. Suresh S (2007) Biomechanics and biophysics of cancer cells. *Acta Materialia*
790 55(12):3989–4014.
- 791 30. Kumar S, Weaver VM (2009) Mechanics, malignancy, and metastasis: The force
792 journey of a tumor cell. *Cancer Metastasis Rev* 28(1-2):113–127.

- 793 31. Guck J, Chilvers ER (2013) Mechanics meets medicine. *Science Transl Med*
794 5(212):212fs41.
- 795 32. Zheng Y, et al. (2015) Decreased deformability of lymphocytes in chronic lymphocytic
796 leukemia. *Sci Rep* 5:7613–7617.
- 797 33. Lam WA, Rosenbluth MJ, Fletcher DA (2007) Chemotherapy exposure increases
798 leukemia cell stiffness. *Blood* 109(8):3505–3508.
- 799 34. Di Carlo D (2012) A Mechanical Biomarker of Cell State in Medicine. *J Lab Autom*
800 17(1):32–42.
- 801 35. Surcel A, et al. (2015) Pharmacological activation of myosin II paralogs to correct cell
802 mechanics defects. *Proc Natl Acad Sci U S A* 112(5):1428–1433.
- 803 36. Ito C, et al. (1996) Comparative cytotoxicity of dexamethasone and prednisolone in
804 childhood acute lymphoblastic leukemia. *J Clin Oncol* 14(8):2370–2376.
- 805 37. Rosendahl P, et al. (2017) Real-time fluorescence and deformability cytometry - flow
806 cytometry goes mechanics. *bioRxiv*:187435.
- 807 38. Byun S, et al. (2013) Characterizing deformability and surface friction of cancer cells.
808 *Proc Natl Acad Sci U S A* 110(19):7580–7585.
- 809 39. Lange JR, et al. (2015) Microconstriction arrays for high-throughput quantitative
810 measurements of cell mechanical properties. *Biophys J* 109(1):26–34.
- 811 40. Tse HTK, et al. (2013) Quantitative Diagnosis of Malignant Pleural Effusions by
812 Single-Cell Mechanophenotyping. *Science Transl Med* 5(212):212ra163.
- 813 41. Chimini G, Chavrier P (2000) Function of Rho family proteins in actin dynamics
814 during phagocytosis and engulfment. *Nat Cell Biol* 2(10):191–196.
- 815 42. Fletcher DA, Mullins RD (2010) Cell mechanics and the cytoskeleton. *Nature*
816 463(7280):485–492.
- 817 43. Kasza KE, et al. (2007) The cell as a material. *Curr Opin Cell Biol* 19(1):101–107.
- 818 44. Patel NR, et al. (2012) Cell Elasticity Determines Macrophage Function. *PLoS ONE*
819 7(9):e41024.
- 820 45. Salbreux G, Charras G, Paluch E (2012) Actin cortex mechanics and cellular
821 morphogenesis. *Trends Cell Biol* 22(10):536–545.
- 822 46. Rowat AC, Lammerding J, Ipsen JH (2006) Mechanical Properties of the Cell Nucleus
823 and the Effect of Emerin Deficiency. *Biophys J* 91(12):4649–4664.
- 824 47. Munder MC, et al. (2016) A pH-driven transition of the cytoplasm from a fluid- to a
825 solid-like state promotes entry into dormancy. *eLife* 5:e09347.
- 826 48. Trager W, Jensen JB (1976) Human malaria parasites in continuous culture. *Science*
827 193(4254):673–675.
- 828 49. Lelièvre J, Berry A, Benoit-Vical F (2005) An alternative method for Plasmodium

- 829 culture synchronization. *Exp Parasitol* 109(3):195–197.
- 830 50. Lambros C, Vanderberg JP (1979) Synchronization of Plasmodium falciparum
831 erythrocytic stages in culture. *J Parasitol* 65(3):418–420.
- 832 51. Ribaut C, et al. (2008) Concentration and purification by magnetic separation of the
833 erythrocytic stages of all human Plasmodium species. *Malar J* 7(1):45–49.
- 834 52. Bernard GR, et al. (1994) The American-European Consensus Conference on ARDS -
835 Definitions, Mechanisms, Relevant Outcomes, and Clinical-Trial Coordination. *Am J*
836 *Respir Crit Care Med* 149(3):818–824.
- 837 53. Vardiman JW, et al. (2009) The 2008 revision of the World Health Organization
838 (WHO) classification of myeloid neoplasms and acute leukemia: rationale and
839 important changes. *Blood* 114(5):937–951.
- 840 54. Herold C (2017) Mapping of Deformation to Apparent Young's Modulus in Real-Time
841 Deformability Cytometry. *arXiv:1704.00572*.
- 842 55. Herbig M, et al. (2017) Real-time deformability cytometry: label-free functional
843 characterization of cells. *Flow Cytometry Protocols*, eds Hawley R, Hawley TS 4 Ed.
844 doi:10.1007/978-1-4939-7346-0.

845

846



851 **Figure 1—Figure Supplement 1. Definition of RT-DC parameters and illustration of gates. A,**

852 Gating by cell dimensions in μm during RT-DC measurements. A minimum for the size of a cell

853 parallel and perpendicular to the flow direction can be set; so can independent values for the maximum

854 in both directions. Setting the minimum to $5 \mu\text{m}$ pre-excludes erythrocytes and most thrombocytes and

855 focuses the measurement on leukocytes only. Due to their strong deformation in the channel,

856 erythrocytes have a typical size of only $3 \mu\text{m}$ perpendicular to the flow. **B,** The relation between the

857 detected cell contour and the convex hull contour. The convex hull is used for contour smoothing in

858 the calculation of the deformation parameter (see C) as well as for excluding strongly irregular cells

859 whose shape is not primarily the result of the deforming hydrodynamic forces in the channel. This

860 exclusion is mediated by a limit for the area ratio between the convex hull area and the cells original

861 area (see also C). **C,** Calculation of deformation and area ratio as well as five examples of cells per

862 parameter to illustrate the differences. A deformation of 0 and an area ratio of 1 would belong to a

863 perfectly smooth circle. The typical upper limit for the area ratio is set to 1.05, e.g. for all leukocytes.

864 **D,** Cell brightness analysis. When gating for leukocyte subpopulations the mean brightness of all pixel

865 values within the cell contour is used. In addition, the root mean square (RMS) value of the pixel


866 values in a 5×9 pixel area around the cell's center is used. This allows to get rid of possible

867 erythrocyte doublets. Note: The main brightness difference between neutrophils and monocytes is

868 found in a region close to the cell's contour. Also other parameters calculated from the pixel values


869 within the contour, such as the standard deviation, reveal differences between the cell types but are not

870 used in this work.




872
873
874
875
876
877
878
879
880
881
882

Figure 1–Figure Supplement 2. Brightness and cell size of purified leukocyte subpopulations in MORE analysis. **A**, Monocytes (> 70 % pure, as determined by FACS analysis). **B**, Neutrophils (> 95 % pure). **C** Eosinophils (> 90 % pure). **D**, T lymphocytes (> 95 % pure). **E**, B lymphocytes (> 90 % pure). **F**, Basophils, indicated by the grey ellipse (25 % pure, impurities: 63 % neutrophils, 12 % natural killer cells; concurrently assessed by FACS and MORE analysis). While monocytes, neutrophils, and eosinophils overlap by cell size in the range of 55 to 90 μm^2 the cell types are well separated by their cell image brightness without overlap. The brightness of lymphocytes is similar to the brightness of monocytes but cell size is separating both populations without overlap.




883
 884
 885
 886
 887
 888
 889
 890
 891
 892
 893
 894
 895
 896
 897
 898

Figure 1–Figure Supplement 3 | Effect of red blood cell lysis on morpho-rheological properties of leukocytes. Prior to flow cytometric analysis and many other *in vitro* assays targeting peripheral blood or lymphoid tissue suspensions, RBC are commonly removed. To test the effect of the RBC lysis procedure on leukocyte size and deformation we prepared samples according to the manufacturer’s advice (BD Pharm Lyse 555899). Besides using the lysing solution, the procedure comprises gentle vortexing and two centrifugation steps (200 g for 5 min), which might all affect the cells. The resulting cell pellet after RBC lysis was suspended in 50 μ l autologous serum and 950 μ l measurement buffer. As control, 50 μ l whole blood of the same donor was suspended in 950 μ l measurement buffer. Comparison of the morpho-rheological features of leukocytes showed that the RBC lysis procedure inverted the relative amounts of lymphocytes and myeloid cells, yielded lymphocytes that were less deformed, and myeloid cells that were larger and more deformed. Therefore, we consistently used whole blood for analysis, rather than pre-analytical RBC lysis, which also saves time and cost.




899
 900
 901
 902
 903
 904
 905
 906
 907
 908
 909
 910
 911
 912
 913
 914
 915
 916
 917
 918
 919
 920
 921

Figure 1–Figure Supplement 4. Stability of results with anti-coagulant and storage time. **A**, Variation of deformation (left axis, black) and cell size (right axis, blue) of leukocytes and erythrocytes in the experimental procedure of MORE blood analysis. Blood of the same donor was repeatedly drawn and measured ($n = 5$ donors, individual median values as small dots, values normalized by the means thereof, whiskers show \pm standard deviation). **B**, Possible effects of the anticoagulant sodium citrate on the MORE analysis of blood cell deformation and size were investigated by comparing measurements of sodium citrate blood with freshly drawn blood directly (within 2 min) diluted in the measurement buffer. Neither deformation (left axis, black) nor cell size (right axis, blue) were affected by the anticoagulant for any leukocytes or erythrocytes ($n = 5$ donors, individual median values as small dots, means thereof as open squares). **C-E**, Sodium citrate storage effects at room temperature over time regarding deformation (top panel) and cell size (bottom panel) of the majority of leukocytes ($> 95\%$) – neutrophils, lymphocytes, and monocytes. Relative values were calculated against the respective initial measurement directly (within 20 minutes) post blood drawing. Within the first two hours stable results are obtained with the single exception for the deformation of lymphocytes. But also lymphocytes deformation remains stable within 30 to 120 min post blood drawing after an initial drop of about 10-15 % (mean values of individual median values as open squares). Of note, in pathological conditions deformation and size change after drawing blood, so that the amount of change itself could actually be a diagnostic parameter. An advantage of RT-DC is that leukocyte mechanics can be measured within 15 min after blood drawing, which is not possible with other techniques where significant time is spent on separation/preparation. All error bars represent the standard deviation.



922
 923
 924
 925
 926
 927
 928
 929
 930
 931


Figure 1–Figure Supplement 5. Inter-donor variation of deformation and cell size. Values shown are median values for each donor’s individual cell types, normalized by the mean for all 21 donors (10 male – blue; 11 female – red) for each respective cell type. See also Main Text Figure 1E for absolute values. Relative values are used for better illustration of the variance within the different cell types: **A**, neutrophils; **B**, lymphocytes; **C**, monocytes; **D**, eosinophils; **E**, erythrocytes. Each panel contains the gray 95 % confidence ellipse displaying the norm for the respective cell types. Comparison of the male and female groups shows no significant difference for any of the cell types.



932
933

934 **Figure 1–Figure Supplement 6. Intra-day variation of deformation and cell size.** In a 24 hour time
 935 course we monitored the intra-day variation of the median values of deformation and cell size for **A**,
 936 neutrophils; **B**, lymphocytes; **C**, monocytes and so, typically, more than 95 % of all leukocytes (2
 937 donors; donor 1: blue, donor 2: magenta). The time course started in the afternoon/evening of the first
 938 day and ended at noon/afternoon of the following day. For the first measurement in the morning,
 939 blood was drawn from the donor prior to getting up. Variation in deformation was small and even less
 940 in cell size and compared in range with our experimental uncertainty as determined in Figure 1–Figure
 941 Supplement 4A. The small variance is illustrated in **D-F** by comparing the individual donor intra-day
 942 variation to the inter-donor variation from Figure 1–Figure Supplement 5. For each donor, the relative
 943 deformation and cell size values were obtained by normalization to their respective mean values of the
 944 24 hour time course. In addition to the data points (same color and shape coding as in A-C) the 95 %
 945 confidence ellipses are shown as shadows in the same color. The small intra-day variation of size and
 946 deformation led us to conclude that the variation within physiological blood sugar, electrolyte, and
 947 hormone levels as well as daily cell count variation did not call for special measures regarding the
 948 drawing of blood for MORE analysis, e.g., at a certain time of day, or fasting. **G-I**, 68 % (inner shade)
 949 and 95 % (outer shade) confidence regions of a single measurement for **G**, neutrophils; **H**,
 950 lymphocytes; and **I**, monocytes. The single measurement confidence is based on 12 repeated
 951 measurements in total for the two donors in A-C. Therefore, the confidence regions reflect possible
 952 variations for the individual cell types on a technical level, such as small differences in sample
 953 handling, as well as on the biological level, such as intra donor variations.

954



955

956

957

958

959

960

961


962

963

964


965

Figure 2–Figure Supplement 1. Comparison of erythrocytes in spherocytosis with the healthy control. Erythrocytes in spherocytosis ($n = 4$ patients, see also main text Figure 2C) show a statistically significant lower deformation of 0.28 ± 0.02 compared to the healthy norm ($n = 21$ donors, known from main text Figure 1E and Figure 1–Figure Supplement 5) with a deformation of 0.35 ± 0.01 (mean \pm SD, $p = 0.002$). The cell size in spherocytosis was found to be significantly smaller at $37.8 \pm 1.8 \mu\text{m}^2$ compared to $40.1 \pm 0.9 \mu\text{m}^2$ (mean \pm SD, $p = 0.004$) for erythrocytes in the healthy control group. Asterisks indicate statistically significant differences, $p < 0.05$, by Kruskal-Wallis test. Error bars represent the standard deviation.




966
 967
 968
 969
 970
 971
 972
 973
 974
 975
 976
 977
 978
 979
 980
 981
 982
 983
 984

Figure 2–Figure Supplement 2. *In vitro* infection of erythrocytes with *Plasmodium falciparum*. **A**, Erythrocytes at different stage of infection in a standard blood smear. Scale bar 10 μm . **B**, Pictures of erythrocytes in MORE analysis. Cells displaying distinct bright spots are exclusively found in *P.f.* exposed and infected samples and are therefore considered infected cells. Scale bar 10 μm . **C**, Parasitemia of *in vitro* infection experiments as determined from the blood smear (black) and the fraction of cells clearly detected as infected cells by MORE analysis (red) over the time course of 46 h. The efficiency of the detection of infected cells in MORE analysis increases with time, possibly due to the growth of the parasites. The deviation from the parasitemia as determined by the blood smear is in part caused by conservative gating settings for the automated identification of infected cells in MORE analysis with the goal of preventing false positive results. The difference could in part also stem from the bright spot being the vacuole forming inside the cell, and not the actual parasite. **D**, 46 hour time course of an *in vitro* malaria infection in erythrocytes displaying the development of deformation and cell size of the erythrocyte populations in the control sample (top row) and two separate exposed and infected samples (middle and bottom row). In addition, red dots indicate those cells identified as infected by MORE analysis. The time course of the median deformation values of the populations is summarized in main text Figure 3C.




985
 986
 987
 988
 989
 990
 991
 992
 993
 994
 995
 996
 997
 998
 999
 1000
 1001
 1002
 1003
 1004
 1005
 1006

Figure 3–Figure Supplement 1. Neutrophil response in blood during *in vitro* and *in vivo* stimulation. **A** and **B**, change of deformation and cell size of neutrophils over time after *in vitro* fMLP stimulation of diluted whole blood. Relative median values are obtained by normalization to the respective values before stimulation. Blue dots: individual median values of stimulated samples, $n = 5$ donors. Open squares: mean values thereof. Gray dots: individual median values of control samples treated equally to stimulated samples without fMLP, $n = 3$ donors. Gray bars: Intervals, indicating 68 % and 95 % confidence of all control measurements ($n = 12$). Asterisks indicate statistically significant differences between all control measurements and stimulated samples, $p < 0.05$. After fMLP stimulation, neutrophils show an initial drop in deformation and cell size, followed by a complete change to significantly larger and more deformed cells at later stages of the stimulation. **C** and **D**, change of deformation and cell size of neutrophils in patient blood after LPS inhalation. Blood samples were drawn freshly at each time point and measured within 15 min after blood withdrawal. Relative median values are obtained by normalization to the respective values prior to stimulation. Blue dots: individual median values of stimulated samples, $n = 2$ donors. Open squares: mean values of thereof. Asterisks indicate statistically significant differences to the reference measurements before stimulation, $p < 0.05$. At two hours post LPS inhalation there was a significant increase in both deformation and cell size of neutrophils in the blood of otherwise healthy human volunteers. These values returned to and remained at the baseline one hour later. All error bars represent the standard deviation.




1007
 1008
 1009
 1010
 1011
 1012
 1013
 1014
 1015
 1016
 1017
 1018
 1019
 1020
 1021
 1022
 1023
 1024

Figure 3–Figure Supplement 2. *In vitro* stimulation of blood with *Staphylococcus aureus*. **A** and **B**, change of deformation and cell size shown for neutrophils, lymphocytes and monocytes of *S. aureus* stimulated blood relative to the respective control before stimulation. Blue dots: medians of stimulated blood cells, $n = 4$ donors; open squares: mean values and standard deviation of four experiments; asterisks indicate differences to the reference measurements before stimulation, $p < 0.05$ by Kruskal-Wallis test. Cell size and deformation of stimulated neutrophils are significantly increased when compared to the baseline before stimulation. Lymphocytes show strong variations but without any clear trend that is also not found for monocytes. A comparison of *S. aureus* stimulated blood and the healthy norm known from Figure 1–Figure Supplement 5 reveals similar results. In panels **C–E**, the norm is shown by the individual median values (gray dots, $n = 21$ donors) for **C**, neutrophils; **D**, monocytes; and **E**, lymphocytes with the 68 % and 95 % confidence ellipses as gray shadows. Median values of the stimulated samples ($n = 4$ donors) are displayed as green hexagons and normalized to the average values of the norm. **F**, Separate quantification of deformation and cell size of data shown in **C–E** as mean and standard deviation. Asterisks indicate statistically significant differences to the norm ($p < 0.05$ by Kruskal-Wallis test).



1025
 1026
 1027
 1028
 1029
 1030
 1031
 1032
 1033
 1034
 1035

Figure 3—Figure Supplement 3. Single cell distributions of neutrophils, lymphocytes, and monocytes from patients with ALL, RTI, and EBV compared to controls. A-C, exemplary scatter plots of size vs. deformation of **A**, neutrophils; **B**, monocytes; and **C**, lymphocytes in the blood of a patient with ALL (magenta) compared to controls (black). **D-F**, exemplary scatter plots of size vs. deformation of **D**, neutrophils; **E**, monocytes; and **F**, lymphocytes in blood of a patient with RTI (green) compared to controls (black). **G-I**, exemplary scatter plots of size vs. deformation of **G**, neutrophils; **H**, monocytes; and **I**, lymphocytes in blood of a patient with EBV (orange) compared to controls (black).



1037

1038

1039

1040

1041

1042

1043

1044

1045

1046

1047

1048

1049

1050

1051

1052

1053

1054

1055

1056

1057

1058

1059

1060

1061

Figure 4–Figure Supplement 1. Comparison of ALL and AML blast cells with the norm.

A, Deformation and cell size of ALL blasts ($n = 4$ patients, see also main text Figure 4D) are compared to the lymphocyte norm ($n = 21$ donors, known from main text Figure 1E and Figure 1–Figure Supplement 5B). ALL blasts were significantly larger than lymphocytes, while no trend – but a large variation – is detected for the deformation. Deformation and cell size of AML blasts ($n = 7$ patients, see also main text Figure 4D) are compared to the norm of neutrophils, monocytes and eosinophils ($n = 21$ donors, known from main text Figure 1E and Figure 1–Figure Supplement 5D). AML blasts were significantly less deformed than the norm of the three cell types. At the same time the cell size did only show significant differences when compared to the larger eosinophils.

B, Comparison of the apparent Young's modulus of ALL ($n = 4$ patients, see also main text Figure 4D) and AML ($n = 7$ patients, see also main text Figure 4D) blasts with each other and the norm of neutrophils, monocytes and eosinophils ($n = 21$ donors, known from main text Figure 1E and Figure 1–Figure Supplement 5) when treated as purely elastic. ALL blasts are significantly more compliant compared to AML blasts and the norm of monocytes. No statistically significant difference was found in the comparison of ALL blasts and the norm of neutrophils and eosinophils. AML blasts are also significantly stiffer compared to the norm of neutrophils and eosinophils but no statistically significant difference was found in the comparison to the norm of monocytes. Only an upper estimate for the apparent Young's modulus of 0.5 kPa can be given for lymphocytes because most deformation and size values for this cell type are located outside the region of stable results from the numerical simulation that was used to convert deformation and cell size data to apparent Young's moduli. Asterisks indicate statistically significant differences, $p < 0.05$ by Kruskal-Wallis test. Error bars represent the standard deviation.

1062 **RICH MEDIA FILES**

1063

1064 **Movie S1. RT-DC in action.** Video of the microfluidic channel system during RT-DC
1065 measurement of diluted whole blood. The cell suspension flows from left to right through the
1066 channel. Cells enter on the left and are focused by sheath flow from the top and bottom of the
1067 frame towards the narrow RT-DC measurement channel of 300 μm length and 20 μm width
1068 and height in the right half of the image. RT-DC measurements are carried out on the cells
1069 that travel through the last third of the length of the measurement channel.

1070

1071 **Movie S2. 3D visualization of the separation of leukocyte populations.** Rotating angle
1072 view in the space of deformation, cell size and cell brightness. Cell identification in order of
1073 appearance by coloring: lymphocytes (blue), neutrophil granulocytes (black), eosinophil
1074 granulocytes (cyan), monocytes (orange), basophil granulocytes (green).

1075

1076

1077

1078 **SUPPLEMENTARY FILES**

1079

1080 **Supplementary file 1. Table of relative blood counts by MORE analysis and**
1081 **conventional analysis.** Percentage of all leukocytes identified by MORE analysis compare to
1082 conventional full blood cell counts, obtained with Sysmex XE-5000 differential analyzer and
1083 verified by a microscopic differential count, of four donors, two male (A, C), two female (B,
1084 D). The absolute cell counts per volume obtained by MORE analysis differ from the values of
1085 the conventional blood count, since some cells are not detected (up to 40 % of all cells).
1086 However, this affects all leukocytes similarly so that the relative counts are not changed.

1087

1088 **Supplementary file 2. Table comparing conventional biomarkers of leukemia with**
1089 **MORE analysis.**

1090 **1) Morphological analysis** of air-dried Romanowsky (Wright, Wright-Giemsa, or May-
1091 Grünwald- Giemsa)-stained blood or bone marrow smears. The morphological features
1092 identified by microscopic examination may suggest either lymphoid or myeloid

1093 differentiation of leukemic cells, but with the exception of the identification of Auer rods in
1094 myeloblasts none of these features is lineage-specific. Sub-clones can be identified by
1095 differences in size and morphological features (e. g. cytoplasmatic vacuoles).

1096 **2) Cytochemical staining** improves the accuracy and reproducibility of lineage assessment
1097 and therefore is required for traditional sub-classification of acute myeloid leukemia (AML)
1098 according to the French-American-British (FAB) and WHO criteria. Sudan Black and stains
1099 for myeloperoxidase (MPO) to identify myeloblasts and esterase stains like alpha-naphthyl-
1100 butyrate to identify monoblasts have remained useful in this regard. Staining must be
1101 performed without undue delay as MPO is unstable and becomes undetectable after a week of
1102 storage.

1103 **3) Immunophenotypic classification** is based on identification of cell surface epitopes or
1104 cytoplasmatic proteins by fluorescent dye-labeled antibodies. Flow cytometry (fluorescence-
1105 activated cell sorting, FACS) is nowadays widely used as a particularly powerful method
1106 because multiparameter analysis offers the advantage of segregating leukemic cells from non-
1107 neoplastic cells. Thus, rapid analysis allows to establish the lineage of the leukemia (e.g.
1108 myeloid versus lymphoid), its stage of differentiation (e. g. T- versus B-ALL) and facilitates
1109 minimal residual disease (MRD) monitoring using a leukemia-specific pattern of markers not
1110 expressed in that combination on regular blood or bone marrow cells. Notably, some
1111 precursor B-cell ALL might be negative for CD45 (leukocyte common antigen) or patients
1112 with T-ALL lack TdT or CD34 expression. Although ALL can be classified according to the

1113 stage of maturation, the optimal immunologic sub-classification remains a matter of debate.
1114 Many ALLs also aberrantly express myeloid-lineage associated antigens (mostly CD13,
1115 CD33). Therefore the antibody screening panel for acute leukemias must be designed to
1116 include at least one very sensitive and one relatively specific marker for each hematopoietic
1117 and lymphoid lineage.

1118 **4) Molecular (genetic) classification** using traditional methods will detect specific
1119 cytogenetic and/or molecular abnormalities in 60 – 80% of ALL and 50 – 60% of AML cases.
1120 The recent advent of whole genome analysis has allowed virtually all acute leukemias to be
1121 classified according to specific genetic abnormalities. Markers can be separated into
1122 leukemia-specific (e.g. BCR-ABL1; t(15;18)) or leukemic-clone specific (e.g. Ig-heavy chain
1123 gene rearrangements, T-cell receptor gene rearrangements). Both are valuable for
1124 classification, as prognostic indicators with a defined treatment applied, and are nowadays
1125 routinely used for monitoring of MRD by exploiting the high sensitivity of PCR-based
1126 amplification of specific gene sequences. The technique is time-consuming and expensive,
1127 and usually performed only in reference laboratories.

1128 **5) MORE analysis.** When compared to these established conventional methods, the
1129 advantages of morpho-rheological (MORE) phenotyping are characterized by a very short
1130 time for analysis and the minimum amount of blood required. The technique has comparable
1131 power with regard to the identification of leukemic cells and the identification of leukemic
1132 sub-clones. Its applicability to classify the leukemic lineage (for example by significant
1133 differences in size, deformation, and Young's modulus; see Figure 4–Figure Supplement 1)
1134 and to detect small numbers of leukemic cells can theoretically be expected and has been
1135 shown in single cases already, but still has to be tested and proven in a formal comparison,
1136 which is beyond the scope of the present study. Potentially, the rheological features of blast
1137 cells might represent additional prognostic biomarkers for leukemic cells (stiffness might
1138 correlate to drug sensitivity or refractoriness, or identify a leukemic subclone), which will be
1139 the subject of future studies. Morpho-rheological phenotyping, thus, compares very well to
1140 established biomarkers for following ALL treatment success.

1141